A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus

Inclusion Criteria: * Physician-diagnosis of T2DM * On a stable dose of metformin 2000 mg per day for at least 3 months prior to screening. * stable glycaemic control indicated by no change in treatment for diabetes within 3 months prior to screening * HbA1c (Hemoglobin A1c) ≤ 8.5% at screening * Body Mass Index (BMI) within the range 18.5 to 35 kg/m2 , inclusive, at screening. Exclusion Criteria: * Physician diagnosis of type 1 diabetes. * History of any clinically important disease or disorder. * History or presence of chronic Gastrointestinal, hepatic, renal, or pancreatic disease * History of Human immunodeficiency viruses (HIV) infection or a positive HIV test. * History of prior episode(s) of lactic acidosis.